Per the agreement, Eli Lilly receives non-exclusive commercial rights for the application of ProteoNic’s recombinant protein production technology. The licensee company will use this technology for future product development.
2G UNic is a mammalian protein expression technology designed to improve recombinant cell line production levels in host cells, selection systems, and protein targets. According to ProteoNic, this technology exerts a positive effect on recombinant protein production levels and on the stability of expression.
Additionally, ProteoNic licensed the same protein production technology to Aragen Bioscience. While ProteoNic was not able to provide further comment on its deal with Eli Lilly, ProteoNic’s spokesperson Victor Schut told us about the platform at the time of its deal with Aragen.
Schut told us, “We incorporate our DNA elements into existing client production vectors as an improvement of those vectors and production cell lines or we supply our own complete vectors. Both approaches result in higher protein production yields.”
Previously ProteoNic licensed a vector gene delivery system to Horizon Discovery. The licensed technology, CHOGUN, introduces genetic materials into CHO cells that lack the gene encoding enzyme glutamine synthetase, without using the toxic methionine sulphoximine material that is used in the traditional process.
Financial details of the agreement with Eli Lilly were not disclosed.